SG3 Management’s Regenxbio RGNX Stock Holding History

SG3 Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,000	Closed	-$536K	–	1274
2021 Q1	$512K	Buy	+15,000	New	+$640K	0.01%	770
2019 Q2	–	Sell	-2,000	Closed	-$115K	–	492
2019 Q1	$115K	Buy	+2,000	New	+$99.1K	0.01%	251

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG3 Management's RGNX Position: Q2 2021 in Review

SG3 Management sold out of Regenxbio (RGNX) in Q2 2021, closing a stake of 15,000 shares — an estimated $536K sold.

SG3 Management first reported a position in RGNX in Q1 2019 and held it in 2 quarters. The position peaked at $512K in Q1 2021. 172 funds tracked by Wall St. Rank hold RGNX as of Q2 2021.

SG3 Management reported no remaining Regenxbio position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 15,000 Regenxbio shares in Q2 2021, an estimated $536K.
SG3 Management first reported a position in Regenxbio in Q1 2019 and held it in 2 quarters.
SG3 Management's Regenxbio position peaked at $512K in Q1 2021.
172 funds tracked by Wall St. Rank held Regenxbio as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.